Hesham Abdullah Eliwa

Dr. Hesham Abdullah Eliwa


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

21 June 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HSHeba Muneer El sorogy
Heba Muneer El sorogy
Sahar FayezSahar Fayez
Sahar Fayez
IKIslam A Khalil
Islam A Khalil
GJGehad Abdel Jaleel
Gehad Abdel Jaleel
AFAhmed M. Fayez
Ahmed M. Fayez
HThoda El Sayed teba
hoda El Sayed teba
Management of rheumatoid arthritis (RA) requires long-term administration of different medications since there has been no cure until now. Etodolac (ETD) is a nonsteroidal anti-inflammatory drug commonly used for RA management. However, its long-term administration resulted in severe side effects. This study aimed to develop a transdermal in situ gel incorporating ETD-loaded polymeric nanoparticles (NPs) to target the affected joints for long-term management of RA. Several PLGA NPs incorporating 1% ETD were prepared by nanoprecipitation and optimized according to the central composite design. The optimum NPs (F1) exhibited 96.19 ± 2.31% EE, 282.3 ± 0.62 nm PS, 0.383 ± 0.04 PDI, and −6.44 ± 1.69 ZP. A hyaluronate coating was applied to F1 (H-F1) to target activated macrophages at inflammation sites. H-F1 exhibited 287.4 ± 4.2 nm PS, 0.267 ± 0.02 PDI, and −23.7 ± 3.77 ZP. Pluronic F-127 in situ gel (H-F1G) showed complete gelation at 29 °C within 5 min. ETD permeation from H-F1G was sustained over 48 h when applied to microporated skin and exhibited significant enhancement of all permeation parameters. Topical application of H-F1G (equivalent to 8 mg ETD) to Wistarrat microporated skin every 48 h resulted in antirheumatic therapeutic efficacy comparable to commercial oral tablets (10 mg/kg/day).

25 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MAMenna M Abdellatif
Menna M Abdellatif
HEHesham Abdullah Eliwa
Hesham Abdullah Eliwa
MEMohamed Aly Abd El-Aziz El-Degwy
Mohamed Aly Abd El-Aziz El-Degwy
SSSamah Shabana
Samah Shabana
Rafik MounirRafik Mounir
Rafik Mounir
RARehab Abdelmonem
Rehab Abdelmonem
Background/Objectives: This study aimed to develop botanical nanofibers loaded with Psidium guajava leaf extract to heal wounds effectively. Methods: A 23 factorial design was conducted to study the impact of freeze-drying parameters—freezing time, vacuum, and lyophilization time—on the total phenolic and flavonoid content in the lyophilized extract. Then, a polyurethane-based nanofiber dressing loaded with Psidium guajava leaf extract was fabricated using a one-step electrospinning technique. The nanofiber was evaluated considering total polyphenol and flavonoid content, surface roughness, and morphological assessment by scanning electron microscopy. Finally, the nanofiber was evaluated using in vivo wound-healing studies, histopathological analyses, and assessments of tissue levels of tumor necrosis factor-alpha, interleukin-6, matrix metalloproteinase, and growth factors. Results: The optimal conditions for freeze-drying the aqueous extract of Psidium guajava leaves were a freezing time of 24 h, a vacuum adjusted to 0.02 bar, and a lyophilization time of 48 h. The total polyphenol and flavonoid content within the nanofiber was 96 ± 1.2% and 91.83 ± 2.4%, respectively. Incorporating lyophilized extract in the nanofiber led to a decreased roughness average and root mean square roughness of the nanofiber. The nanofiber was continuous and had a smooth, uniform surface. The in vivo wound-healing assay showed superior wound-healing compared to the commercial Panthenol cream. These results were confirmed with histopathological studies. Conclusions: The extraction technique and lyophilization parameters significantly affect the bioactive content of Psidium guajava leaf extract. The botanical-loaded nanofiber showed greater wound-healing potential than a commercial cream, confirming its potential in regenerative medicine and wound repair applications.

10 November 2021 in International Journal of Drug Delivery & Controlled Release
Verified
Journal Article
Open access
PDF file
AEAhmed Adel Alaa- Eldin
Ahmed Adel Alaa- Eldin
MFMohamed Ibrahim Mohamed Fahmy
Mohamed Ibrahim Mohamed Fahmy
HEHesham Abdullah Eliwa
Hesham Abdullah Eliwa
Meptazinol is a centrally acting analgesic belonging to the hexahydro-azepine series, which has demonstrated mixed agonist and antagonist activity at opioid receptors.Receptor binding studies have shown that although meptazinol displays only a low affinity for µ and k opioid receptor sites, it has a some what higher affinity for the subpopulation of µ sites. These binding sites also displays a high affinity for the endogenous opioid peptides, and are thought to be responsible for, among other things, analgesia, but not for the mediation of respiratory depression. A component of its analgesic action is also attributable, in mice at least, to an effect on central cholinergic transmission. In this respect it differs from all conventional analgesic drugs which have been examined (1).Based on this information this drug requires no blocking of opioid receptor during the bioequivalence study. But to achieve the highest degree of safety, close monitoring will be performed to detect the occurrence of any side effect, As well as Anarchole 50mg tablets (Naltrexone, the opioid blocker) will be available at the emergency drugs store to treat any opioid side effect.